Informations:
Erreur:
ID
14599
Description
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00494091
Lien
https://clinicaltrials.gov/show/NCT00494091
Mots-clés
Versions (1)
- 23/04/2016 23/04/2016 -
Téléchargé le
23 avril 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Advanced Renal Cell Carcinoma NCT00494091
Eligibility Advanced Renal Cell Carcinoma NCT00494091
- StudyEvent: Eligibility
Similar models
Eligibility Advanced Renal Cell Carcinoma NCT00494091
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Renal Cell Carcinoma
Item
subjects with histologically confirmed, advanced (stage iv or recurrent disease) rcc. the american joint committee on cancer (ajcc) staging and classification criteria will be used.
boolean
C0007134 (UMLS CUI [1])
ecog performance status
Item
ecog performance status of 0-1.
boolean
C1520224 (UMLS CUI [1])
recist
Item
at least one measurable lesion per recist.
boolean
C1709926 (UMLS CUI [1])
age
Item
age greater than or equal to 20 years.
boolean
C0001779 (UMLS CUI [1])
Asiens
Item
japanese, chinese, or korean ethnicity.
boolean
C0078988 (UMLS CUI [1])
cns metastases
Item
cns metastases at screening or history or cns metastases.
boolean
chemotherapeutic, cytokine-based, or other investigational agents
Item
prior targeted, chemotherapeutic, cytokine-based, or other investigational agents for the treatment of rcc within 4 weeks before first dose of test article. subjects must have documented objective progressive disease after any prior systemic rcc treatment and have recovered to grade 1 or lower toxicities from effects of prior systemic therapy for rcc.
boolean
C1514457 (UMLS CUI [1])
Malignant Neoplasms
Item
in past 5 years, other prior malignancy (except basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ).
boolean
C0006826 (UMLS CUI [1])